Agenus Inc. (AGEN)
NASDAQ: AGEN · IEX Real-Time Price · USD
13.26
+1.14 (9.41%)
At close: May 1, 2024, 4:00 PM
13.70
+0.44 (3.32%)
Pre-market: May 2, 2024, 8:05 AM EDT
Agenus Revenue
In the year 2023, Agenus had annual revenue of $156.31M with 59.47% growth. Revenue in the quarter ending December 31, 2023 was $83.80M with 195.22% year-over-year growth.
Revenue (ttm)
$156.31M
Revenue Growth
+59.47%
P/S Ratio
1.72
Revenue / Employee
$401,835
Employees
389
Market Cap
268.98M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
Dec 31, 2019 | 150.05M | 113.26M | 307.92% |
Dec 31, 2018 | 36.78M | -6.09M | -14.21% |
Dec 31, 2017 | 42.88M | 20.30M | 89.95% |
Dec 31, 2016 | 22.57M | -2.24M | -9.04% |
Dec 31, 2015 | 24.82M | 17.84M | 255.67% |
Dec 31, 2014 | 6.98M | 3.93M | 129.13% |
Dec 31, 2013 | 3.05M | -12.92M | -80.92% |
Dec 31, 2012 | 15.96M | 13.20M | 479.17% |
Dec 31, 2011 | 2.76M | -603.84K | -17.97% |
Dec 31, 2010 | 3.36M | 25.17K | 0.75% |
Dec 31, 2009 | 3.33M | 683.36K | 25.78% |
Dec 31, 2008 | 2.65M | -2.90M | -52.25% |
Dec 31, 2007 | 5.55M | 4.86M | 702.20% |
Dec 31, 2006 | 692.14K | 62.16K | 9.87% |
Dec 31, 2005 | 629.98K | -77.10K | -10.90% |
Dec 31, 2004 | 707.07K | -277.59K | -28.19% |
Dec 31, 2003 | 984.66K | 200.39K | 25.55% |
Dec 31, 2002 | 784.28K | -3.77M | -82.78% |
Dec 31, 2001 | 4.55M | 4.11M | 929.07% |
Dec 31, 2000 | 442.63K | -138.83K | -23.88% |
Dec 31, 1999 | 581.46K | - | - |
Dec 31, 1998 | 0 | - | - |
Dec 31, 1997 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ChromaDex | 83.57M |
EDAP TMS | 67.14M |
Sanara MedTech | 64.99M |
Poseida Therapeutics | 64.70M |
Adaptimmune Therapeutics | 60.28M |
Metagenomi | 44.76M |
Nanobiotix | 40.23M |
Nyxoah | 4.83M |
AGEN News
- 1 day ago - Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement - Business Wire
- 7 days ago - Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting - Business Wire
- 8 days ago - Top 2 Health Care Stocks Which Could Rescue Your Portfolio This Month - Agenus (NASDAQ:AGEN), MultiPlan (NYSE:MPLN) - Benzinga
- 9 days ago - Agenus to Provide First Quarter 2024 Financial Report and Corporate Update - Business Wire
- 20 days ago - Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer - Business Wire
- 26 days ago - Agenus Announces Reverse Stock Split of Common Stock - Business Wire
- 7 weeks ago - Agenus Reports Fourth Quarter and Full Year 2023 Results - Business Wire
- 2 months ago - Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024 - Business Wire